That’s compared to a close of $36 on the day before. Unfortunately for DCPH stock shareholders, this one plummeted over 75%, closing at $8.82 on Nov. The full results from the INTRIGUE Phase 3 clinical study are expected to be presented at an upcoming medical meeting.”īiotech names either surge or tank on announcements related to clinical trials. “While we are disappointed with these results we believe this was a robust, well-designed, and well-executed study. The announcement stated, “The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care sunitinib.” CEO Steve Hoerter noted the following: 5, the company also announced results from its INTRIGUE Phase 3 Clinical Study. 7 Travel Stocks to Pack in Your Portfolio Ahead of Holiday Trips.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |